Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma

[1]  B. Vincenzi,et al.  Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[2]  C. Tournigand,et al.  1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial , 2022, Annals of Oncology.

[3]  C. Tournigand,et al.  Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. , 2022, The Lancet. Oncology.

[4]  P. Ross-Macdonald,et al.  Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[5]  F. Lohr,et al.  Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.

[6]  P. Validire,et al.  Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s , 2021, Cancer Immunology Research.

[7]  T. Choueiri,et al.  Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. , 2021, European urology oncology.

[8]  G. Sauter,et al.  Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer , 2021, International Urology and Nephrology.

[9]  Lauren L. Ritterhouse,et al.  BAP1-Mutated Clear Cell Renal Cell Carcinoma. , 2020, American journal of clinical pathology.

[10]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[11]  H. Moch,et al.  Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease , 2020, Frontiers in Oncology.

[12]  G. Calin,et al.  Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers , 2020, Frontiers in Cell and Developmental Biology.

[13]  Shankun Zhao,et al.  Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis , 2020, Urologia Internationalis.

[14]  E. Philip,et al.  Genomic profiling in renal cell carcinoma , 2020, Nature Reviews Nephrology.

[15]  M. Di Maio,et al.  Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). , 2020, American journal of clinical oncology.

[16]  R. Motzer,et al.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  E. Yakirevich,et al.  Tumor mutational burden and immune signatures interplay in renal cell carcinoma , 2020, Annals of translational medicine.

[18]  C. Drake,et al.  Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting , 2020, Clinical Cancer Research.

[19]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[20]  R. Motzer,et al.  Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. , 2019, The Lancet. Oncology.

[21]  C. Sautès-Fridman,et al.  Context-dependent roles of complement in cancer , 2019, Nature Reviews Cancer.

[22]  P. Dong,et al.  MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation , 2019, Cancers.

[23]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[24]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[25]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[26]  H. Nakagawa,et al.  Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma , 2019, Cancer science.

[27]  R. Motzer,et al.  Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. , 2018, The Lancet. Oncology.

[28]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[29]  Paul T. Spellman,et al.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma , 2018, Cell reports.

[30]  S. Pal,et al.  The Role of Circulating Tumor DNA in Renal Cell Carcinoma , 2018, Current Treatment Options in Oncology.

[31]  An Zhao,et al.  MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma. , 2016, European urology focus.

[32]  Nicolai J. Birkbak,et al.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.

[33]  G. Halmos,et al.  Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. , 2016, Urologic oncology.

[34]  Patrick Bennett,et al.  Biomarkers: more of a challenge for bioanalysis than expected. , 2016, Bioanalysis.

[35]  E. V. Van Allen,et al.  Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups , 2016, Cancer Immunology Research.

[36]  G. Crabtree,et al.  The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. , 2016, Cold Spring Harbor perspectives in medicine.

[37]  U. Harmenberg,et al.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study , 2016, World Journal of Urology.

[38]  Su-Jin Shin,et al.  Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status , 2016, Annals of Surgical Oncology.

[39]  T. Ho,et al.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation , 2015, Cancer Immunology Research.

[40]  Hong-Jian Zhu,et al.  Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. , 2015, Seminars in cell & developmental biology.

[41]  Y. Kluger,et al.  PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases , 2014, Journal of Cancer.

[42]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[43]  David M. Thomas,et al.  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. , 2013, The Lancet. Oncology.

[44]  K. Cheng,et al.  Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma , 2013, Urologia Internationalis.

[45]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[46]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[47]  Barbara Burwinkel,et al.  Extracellular miRNAs: the mystery of their origin and function. , 2012, Trends in biochemical sciences.

[48]  F. Tsai,et al.  RANKL increases migration of human lung cancer cells through intercellular adhesion molecule‐1 up‐regulation , 2011, Journal of cellular biochemistry.

[49]  Y. Okada,et al.  Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas , 2009, The Journal of pathology.

[50]  Jesper Tegnér,et al.  On reliable discovery of molecular signatures , 2009, BMC Bioinformatics.

[51]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[52]  B. Le Goff,et al.  DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.

[53]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[54]  S. Cross,et al.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.

[55]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Cheville,et al.  Costimulatory B 7-H 1 in renal cell carcinoma patients : Indicator of tumor aggressiveness and potential therapeutic target , 2004 .

[57]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.